Patients with type 2 diabetes mellitus (T2DM) prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have significantly lower one-year mortality, especially those also diagnosed with ...

Funding supports Phase 2b development of clofutriben, a novel HSD-1 inhibitor, with a focus on cortisol-driven metabolic dysfunction in type 2 diabetes PORTLAND, Ore., Sept. 24, 2025 (GLOBE NEWSWIRE) ...

In women with type 2 diabetes (T2D), use of hormone replacement therapy (HRT) skin patches is not associated with a higher risk of blood clots or stroke. However, an increased cardiovascular risk was ...

Between 2006 and 2021, Sweden saw a dramatic rise in early-onset type 2 diabetes (T2D), with the prevalence more than doubling from 0.27% to 0.64% and incidence nearly doubling from 54 to 107 per ...

Artificial intelligence (AI) can match physician insulin dosing, maintaining target blood sugar levels in patients with type 2 diabetes. A study showed an AI-based insulin decision support system's ...

Despite promising adherence and persistence data, tirzepatide dose escalation was slower in the real-world than clinical trials in patients with obesity without T2D. Tirzepatide dose escalation is ...

Oral semaglutide 14 mg was associated with better cardiometabolic outcomes than active comparators, including empaglifozin and liraglutide, among patients with T2D. Oral semaglutide improves ...

Semaglutide increased maximum walking distance by 13% compared with placebo. Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic ...

Wearable mobile health technology could help people with Type 2 Diabetes (T2D) to stick to exercise regimes that help them to keep the condition under control, a new study reveals. An international ...

Chronic kidney disease is a common complication of type 2 diabetes, but not everyone with diabetes develops it. Certain risk factors, like diabetic neuropathy and hypertension, can increase the chance ...

For Jennifer Gowans, a patient ambassador for the American Kidney Fund, helping others is her go-to coping strategy for life with type 2 diabetes and chronic kidney disease. Chronic kidney disease ...

Semaglutide reduced the risk of kidney disease worsening, renal failure, and CV death by 24% compared with placebo. The approval was based on data from the randomized, double-blind, placebo-controlled ...